GTF2H3

Across TCGA pan-cancer cohorts, GTF2H3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GTF2H3 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GTF2H3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GTF2H3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where GTF2H3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.379	0.656	.008	20	view →
LSCC	DFS	Quartile	II,III,IV	0.825	0.363	.005	19	view →
HNSC	OS	Tertile	IV	0.868	0.566	.004	10	view →
LUAD	DFS	Median	II,III,IV	1.000	0.798	.015	3	view →
CCRCC	DFS	Quartile	All	0.892	0.632	.022	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GTF2H3–PDAC (OS)

Open the PDAC breakdown →